Literature DB >> 11768608

Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells.

D O Azorsa1, H E Cunliffe, P S Meltzer.   

Abstract

The steroid receptor coactivator AIB1 (amplified in breast cancer-1) is a transcriptional coactivator which has been found to be amplified in breast cancer. We have now investigated the role of the AIB1 protein in breast cancer cell lines. Although detectable levels of AIB1 were present in most cell lines, high levels of AIB1 expression were observed only in the ER-positive cell lines MCF-7 and BT-474 by western blot analysis. Newly developed monoclonal antibodies (mAbs) were used in several assays to show an association between AIBI and estrogen receptor-alpha (ER). AIB1 and ER co-localized to the nucleus of ER positive cell lines as shown by immunofluorescence microscopy, and a functional association of native AIB1 and ER in MCF-7 nuclear extracts was shown by EMSA. Recombinant ER also recruited AIB1 protein from nuclear extracts, shown by EMSA and by precipitation of ER-complex proteins bound to a biotinylated-ERE DNA target. Additionally, anti-AIB1 mAbs were able to immunoprecipitate ER from nuclear extracts of chemically cross-linked cells but not from uncross-linked cells. Both immunoprecipitation and oligonucleotide precipitation studies demonstrated the presence of p300 and CBP as part of the ER transcriptional complex. These results suggest that AIB1 and ER do associate physically in ER-positive breast cancer cell lines. We propose that in AIB1 amplified breast cancers, a heightened AIB1/ER association may play a crucial role in the progression of these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768608     DOI: 10.1023/a:1012972808558

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Authors:  Ganesh V Raj; Gangadhara Reddy Sareddy; Shihong Ma; Tae-Kyung Lee; Suryavathi Viswanadhapalli; Rui Li; Xihui Liu; Shino Murakami; Chien-Cheng Chen; Wan-Ru Lee; Monica Mann; Samaya Rajeshwari Krishnan; Bikash Manandhar; Vijay K Gonugunta; Douglas Strand; Rajeshwar Rao Tekmal; Jung-Mo Ahn; Ratna K Vadlamudi
Journal:  Elife       Date:  2017-08-08       Impact factor: 8.140

2.  Global characterization of transcriptional impact of the SRC-3 coregulator.

Authors:  Rainer B Lanz; Yaroslava Bulynko; Anna Malovannaya; Paul Labhart; Liguo Wang; Wei Li; Jun Qin; Mary Harper; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2010-02-24

3.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

4.  Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.

Authors:  Monica Mann; Valerie Cortez; Ratna K Vadlamudi
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

5.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Authors:  David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses
Journal:  J Transl Med       Date:  2009-06-11       Impact factor: 5.531

6.  Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.

Authors:  Sarah L Anzick; David O Azorsa; S Stoney Simons; Paul S Meltzer
Journal:  BMC Cancer       Date:  2003-09-10       Impact factor: 4.430

7.  Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity.

Authors:  Sudipan Karmakar; Yetao Jin; Akhilesh K Nagaich
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

8.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

9.  Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators.

Authors:  Zeynep Madak-Erdogan; Tze-Howe Charn; Yan Jiang; Edison T Liu; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Syst Biol       Date:  2013-06-18       Impact factor: 11.429

10.  NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells.

Authors:  Meike Wagner; Michael Koslowski; Claudia Paret; Marcus Schmidt; Ozlem Türeci; Ugur Sahin
Journal:  BMC Cancer       Date:  2013-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.